The semaglutide impurity des-17-Gln-SMT is a structural defect impurity that may be produced during the synthesis or storage of semaglutide (a long-acting GLP-1 receptor agonist hypoglycemic drug). This impurity is missing the 17th glutamine (Gln) in the molecular structure, which may cause changes in drug stability or biological activity. Strict monitoring of such impurities is essential to ensure drug purity, safety and efficacy, and is in compliance with relevant regulatory requirements for drug quality control.
Product Overview
Basic Description |
Structure and function: |
Three-letter sequence |
H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Asp-Val-Arg-Arg-Arg-Arg-Arg-Arg-Gly-CONH2 |
Single letter sequence |
HHAEGTFTSDVSSYLEGAKKEFIAWLVKGDVRRAARRRRG-NH2 |
Molecular formula |
C184H286N52O57S |
Molecular weight |
4062.17 g/mol |
Product Attributes
purity |
>98% |
form |
Lyophilized powder |
Storage conditions |
Store at -20°C/-80°C away from light |